QLJ-27299-54756
3 vaccinations
1 coded response
18 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 492 / MI
- Registered
- 2021-01-25
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-25
Registered in v-safe
-
2021-01-25
Dose 1 — Pfizer-BioNTech
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-01-30
- 2021-01-31
- 2021-02-01
- 2021-02-08
-
2021-02-15
Dose 2 — Pfizer-BioNTech
- 2021-02-22
- 2021-03-08
- 2021-08-19
-
2022-09-24
Dose 3 — Pfizer-BioNTechCo-administered: Flu
- 2022-10-12
- 2022-10-15
- 2022-10-22
- 2022-11-05
- 2022-12-24
-
2023-03-25
Survey response — 6 months, dose 3MedDRA: Malaise, Nasopharyngitis, Oropharyngeal pain, Respiratory tract congestion, Rhinorrhoea, Somnolence — Feeling: GoodMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-25 | Pfizer-BioNTech | |
| 2 | 2021-02-15 | Pfizer-BioNTech | |
| 3 | 2022-09-24 | Pfizer-BioNTech | Flu |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Malaise | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Somnolence | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release